Mobile Menu

Liquid Biopsies: Current Status and Future Directions


With liquid biopsies promising to transform multiple stages of the cancer diagnostic and monitoring journey, patients from across the world can benefit from these minimally invasive tests. On the cusp of a revolution, how can we pull together to bring this technology to patients sooner?

This report will provide you with:

  • An overview of the current status of liquid biopsy technologies and their implementation
  • An understanding of the current clinical trial landscape, and lessons learned from setting up large-scale interventional trials
  • Interviews with key opinion leaders on the future directions of bringing liquid biopsies into routine cancer care
  • Insights into opportunities for utilising novel biomarkers and fluids for non-invasive cancer diagnostics

Report Contributors:

  • Anca Oniscu, Consultant Pathologist, Royal Infirmary Edinburgh
  • Chris Abbosh, Principal Clinical Research Fellow, University College London
  • Dominic Rothwell, Nucleic Acids Biomarkers Laboratory, Cancer Research UK Manchester Institute
  • James Black, Postdoctoral Scientist, University College London
  • Klaus Pantel, Chairman, Institute of Tumour Biology, University Medical Center Hamburg-Eppendorf
  • Lauren Leiman, Executive Director, BLOODPAC
  • Maria Jose Serrano, Associate Professor, University of Granada
  • Michael Hubank, Director of Clinical Genomics, Royal Marsden Hospital & Professor of Translational Genomics, ICR 
  • Remond Fijneman, Associate Group Leader, Netherlands Cancer Institute
  • Tina Moser, Postdoctoral Researcher, Medical University of Graz


  • Chapter 1: Introduction and biology
  • Chapter 2: Applications
  • Chapter 3: Liquid Biopsies in clinical trials
  • Chapter 4: Moving towards routine implementation – where are we now?
  • Chapter 5: Opportunities for novel biomarkers and other fluids
  • Chapter 6: Future directions

Download Report:


More on these topics

Liquid Biopsy

Share this report